Attached files

file filename
10-K - FORM 10-K - Azur Pharma Public Ltd Cod297275d10k.htm
EX-4.3 - FORM OF JAZZ PHARMACEUTICALS PLC WARRANT TO PURCHASE ORDINARY SHARES - Azur Pharma Public Ltd Cod297275dex43.htm
EX-4.6 - FORM OF JAZZ PHARMACEUTICALS PLC WARRANT TO PURCHASE ORDINARY SHARES - Azur Pharma Public Ltd Cod297275dex46.htm
EX-4.4 - FORM OF JAZZ PHARMACEUTICALS PLC WARRANT TO PURCHASE ORDINARY SHARES - Azur Pharma Public Ltd Cod297275dex44.htm
EX-32.1 - CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350 - Azur Pharma Public Ltd Cod297275dex321.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULES 13A-14(A) AND 15D-14(A) - Azur Pharma Public Ltd Cod297275dex311.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULES 13A-14(A) AND 15D-14(A) - Azur Pharma Public Ltd Cod297275dex312.htm
EX-4.7B - ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT - Azur Pharma Public Ltd Cod297275dex47b.htm
EX-21.1 - SUBSIDIARIES OF JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY - Azur Pharma Public Ltd Cod297275dex211.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Azur Pharma Public Ltd Cod297275dex231.htm
EX-4.2E - ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT - Azur Pharma Public Ltd Cod297275dex42e.htm
EX-10.42 - FORM OF RESTRICTED STOCK UNIT GRANT NOTICE AND FORM OF RESTRICTED STOCK UNIT.... - Azur Pharma Public Ltd Cod297275dex1042.htm
EX-10.27 - SEPARATION AGREEMENT - Azur Pharma Public Ltd Cod297275dex1027.htm
EX-10.43 - FORM OF RESTRICTED STOCK UNIT GRANT NOTICE AND FORM OF RESTRICTED STOCK UNIT... - Azur Pharma Public Ltd Cod297275dex1043.htm
EX-10.32 - JAZZ PHARMACEUTICALS PLC NON-EMPLOYEE DIRECTOR COMPENSATION ARRANGEMENTS - Azur Pharma Public Ltd Cod297275dex1032.htm
EX-10.31 - SECOND AMENDMENT OF LEASE - Azur Pharma Public Ltd Cod297275dex1031.htm
EX-10.19 - JAZZ PHARMACEUTICALS PLC 2007 EMPLOYEE STOCK PURCHASE PLAN OFFERING DOCUMENT - Azur Pharma Public Ltd Cod297275dex1019.htm
EX-10.41 - FORM OF STOCK OPTION GRANT NOTICE AND FORM OF OPTION AGREEMENT (IRISH) - Azur Pharma Public Ltd Cod297275dex1041.htm
EX-10.34 - JAZZ PHARMACEUTICALS PLC AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL AND... - Azur Pharma Public Ltd Cod297275dex1034.htm
EX-10.33 - JAZZ PHARMACEUTICALS PLC CASH BONUS PLAN - Azur Pharma Public Ltd Cod297275dex1033.htm
EX-10.40 - FORM OF OPTION GRANT NOTICE AND FORM OF STOCK OPTION AGREEMENT - Azur Pharma Public Ltd Cod297275dex1040.htm
EX-10.38 - FORM OF RESTRICTED STOCK UNIT GRANT NOTICE AND FORM OF RESTRICTED STOCK UNIT.... - Azur Pharma Public Ltd Cod297275dex1038.htm
EX-10.37 - FORM OF RESTRICTED STOCK UNIT GRANT NOTICE AND FORM OF RESTRICTED STOCK UNIT.... - Azur Pharma Public Ltd Cod297275dex1037.htm
EX-10.35 - FORM OF OPTION GRANT NOTICE AND FORM OF STOCK OPTION AGREEMENT - Azur Pharma Public Ltd Cod297275dex1035.htm
EX-10.36 - FORM OF STOCK OPTION GRANT NOTICE AND FORM OF OPTION AGREEMENT (IRISH) - Azur Pharma Public Ltd Cod297275dex1036.htm
EX-10.39B - JAZZ PHARMACEUTICALS PLC 2011 EQUITY INCENTIVE PLAN SUB-PLAN GOVERNING AWARDS... - Azur Pharma Public Ltd Cod297275dex1039b.htm
EX-10.3B - JAZZ PHARMACEUTICALS PLC 2007 EQUITY INCENTIVE PLAN SUB-PLAN GOVERNING AWARDS - Azur Pharma Public Ltd Cod297275dex103b.htm

EXHIBIT 4.5

JAZZ PHARMACEUTICALS PLC

WARRANT TO PURCHASE SHARES

To Purchase [             ] Ordinary Shares of US$0.0001 each

Date of Issuance: January 18, 2012

VOID AFTER JULY 21, 2014

THIS CERTIFIES THAT, for value received, [                    ], or permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from Jazz Pharmaceuticals plc, an Irish incorporated public limited company (the “Company”), up to [                    ] ordinary shares of US$0.0001 each in the capital of the Company (the “Ordinary Shares”). This warrant is one of a series of warrants issued by the Company as of the date hereof (individually a “Warrant”; collectively, “Company Warrants”) pursuant to those certain subscription agreements between Jazz Pharmaceuticals, Inc. and each of the Investors, each dated as of July 15, 2008 (each, a “Subscription Agreement”).

 

1. DEFINITIONS. Capitalized terms used herein but not otherwise defined herein shall have their respective meanings as set forth in the Subscription Agreement. As used herein, the following terms shall have the following respective meanings:

 

  (A) Business Day” means a day, other than a Saturday or a Sunday, on which banks in New York City and Dublin are open for the general transaction of business.

 

  (B) Eligible Market” means any of the New York Stock Exchange, The NASDAQ Global Market, The NASDAQ Global Select Market or The NASDAQ Capital Market.

 

  (C) Exercise Period” shall mean the period ending on July 21 2014, unless sooner terminated as provided below.

 

  (D) Exercise Price” shall mean $7.37 per share, subject to adjustment pursuant to Section 4 below.

 

  (E) Exercise Shares” shall mean the Ordinary Shares of US$0.0001 each in the capital of the Company issuable upon exercise of this Warrant.

 

  (F) Trading Day” shall mean (a) any day on which the Ordinary Shares are listed or quoted and traded on their primary Trading Market, (b) if the Ordinary Shares are not then listed or quoted and traded on any Eligible Market, then a day on which trading occurs on the OTC Bulletin Board (or any successor thereto), or (c) if trading does not occur on the OTC Bulletin Board (or any successor thereto), any Business Day.

 

  (G) Trading Market” shall mean the OTC Bulletin Board or any other Eligible Market, or any national securities exchange, market or trading or quotation facility on which the Ordinary Shares are then listed or quoted.

 

2. EXERCISE OF WARRANT. The rights represented by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by delivery of the following to the Company at 3180 Porter Drive, Palo Alto, CA 94304 (Att: General Counsel) (or at such other address as it may designate by notice in writing to the Holder);

 

  (A) An executed Notice of Exercise in the form attached hereto;

 

  (B) Payment of the Exercise Price either in cash or by cheque or by wire transfer to an account designated in writing by the Company; and

 

  (C) This Warrant.


Execution and delivery of the Notice of Exercise shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Exercise Shares, if any.

Certificates for shares purchased hereunder shall be transmitted by the transfer agent of the Company to the Holder by crediting the account of the Holder’s prime broker with the Depository Trust Company through its Deposit Withdrawal Agent Commission system if the Company is a participant in such system, and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise within three business days from the delivery to the Company of the Notice of Exercise, surrender of this Warrant and payment of the aggregate Exercise Price as set forth above. This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the Company.

The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock transfer books are open.

Subject to the final sentence of this paragraph and to the extent permitted by law, the Company’s obligations to issue and deliver Exercise Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any person or entity or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other person or entity of any obligation to the Company or any violation or alleged violation of law by the Holder or any other person or entity, and irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Exercise Shares. The Holder shall, subject to the following proviso, have the right to pursue any remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver Exercise Shares upon exercise of this Warrant as required pursuant to the terms hereof; provided, however, that notwithstanding anything to the contrary in this Warrant or in the Subscription Agreements, if the Company is for any reason unable to deliver Exercise Shares upon exercise of this Warrant as required pursuant to the terms hereof, the Company shall have no obligation to pay to the Holder any cash or other consideration or otherwise “net cash settle” this Warrant.

 

2.1. ISSUANCE OF NEW WARRANTS. Upon any partial exercise of this Warrant, the Company, at its expense, will forthwith and, in any event within five Business Days, issue and deliver to the Holder a new warrant or warrants of like tenor, registered in the name of the Holder, exercisable, in the aggregate, for the balance of the number of Ordinary Shares remaining available for purchase under this Warrant.

 

2.2. PAYMENT OF TAXES AND EXPENSES. The Company shall pay any recording, filing, stamp or similar tax which may be payable in respect of any transfer involved in the issuance of, and the preparation and delivery of certificates (if applicable) representing, (i) any Exercise Shares purchased upon exercise of this Warrant and/or (ii) new or replacement warrants in the Holder’s name or the name of any transferee of all or any portion of this Warrant; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance, delivery or registration of any certificates for Exercise Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Exercise Shares upon exercise hereof.

 

3. COVENANTS OF THE COMPANY.

 

3.1.

COVENANTS AS TO EXERCISE SHARES. The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid up and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number of Ordinary Shares to provide for the exercise of the rights represented by this

 

2


  Warrant. If at any time during the Exercise Period the number of authorized but unissued Ordinary Shares shall not be sufficient to permit exercise of this Warrant, the Company will use its commercially reasonable efforts to take such corporate action in compliance with applicable law as may, in the opinion of its counsel, be necessary to increase its authorized but unissued Ordinary Shares to such number of shares as shall be sufficient for such purposes.

 

3.2. NOTICES OF RECORD DATE AND CERTAIN OTHER EVENTS. In the event of any taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, the Company shall mail to the Holder, at least fifteen (15) days prior to the date on which any such record is to be taken for the purpose of such dividend or distribution, a notice specifying such date. In the event of any voluntary dissolution, liquidation or winding up of the Company, the Company shall mail to the Holder, at least fifteen (15) days prior to the date of the occurrence of any such event, a notice specifying such date. In the event the Company authorizes or approves, enters into any agreement contemplating, or solicits stockholder approval for any Fundamental Transaction, as defined in Section 6 herein, the Company shall mail to the Holder, at least fifteen (15) days prior to the date of the occurrence of such event, a notice specifying such date. Notwithstanding the foregoing, the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice.

 

4. ADJUSTMENT OF EXERCISE PRICE AND SHARES.

The Exercise Price and number of Exercise Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 4.

 

  (A) If the Company, at any time while this Warrant is outstanding, (i) pays a dividend on its Ordinary Shares or otherwise makes a distribution on any class of capital stock that is payable in Ordinary Shares, (ii) subdivides outstanding Ordinary Shares into a larger number of shares, or (iii) combines outstanding Ordinary Shares into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares outstanding immediately before such event and of which the denominator shall be the number of Ordinary Shares outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.

 

  (B) If the Company, at any time while this Warrant is outstanding, distributes to holders of Ordinary Shares (i) evidences of its indebtedness, (ii) any security (other than a distribution of Ordinary Shares covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) any other asset (in each case, “Distributed Property”), then in each such case the Holder shall be entitled upon exercise of this Warrant for the purchase of any or all of the Exercise Shares, to receive the amount of Distributed Property which would have been payable to the Holder had such Holder been the holder of such Exercise Shares on the record date for the determination of shareholders entitled to such Distributed Property. The Company will at all times set aside in escrow and keep available for distribution to such holder upon exercise of this Warrant a portion of the Distributed Property to satisfy the distribution to which such Holder is entitled pursuant to the preceding sentence.

 

  (C) Upon the occurrence of each adjustment pursuant to this Section 4, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Exercise Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.

 

5.

FRACTIONAL SHARES. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise

 

3


  would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the number of Exercise Shares to be issued will be rounded down to the nearest whole share.

 

6. FUNDAMENTAL TRANSACTIONS. If any capital reorganization, reclassification of the share capital of the Company, consolidation or merger of the Company with another entity in which the Company is not the survivor, or sale, transfer or other disposition of all or substantially all of the Company’s assets to another entity shall be effected (any such transaction being hereinafter referred to as a “Fundamental Transaction”), then the Company shall use its commercially reasonable efforts to ensure that lawful and adequate provision shall be made whereby the Holder shall thereafter have the right to purchase and receive upon the basis and upon the terms and conditions herein specified and in lieu of the Exercise Shares immediately theretofore issuable upon exercise of this Warrant, such shares of stock, securities or assets as would have been issuable or payable with respect to or in exchange for a number of Exercise Shares equal to the number of Exercise Shares immediately theretofore issuable upon exercise of this Warrant, had such reorganization, reclassification, consolidation, merger, sale, transfer or other disposition not taken place, and in any such case appropriate provision shall be made with respect to the rights and interests of the Holder to the end that the provisions hereof (including, without limitation, provision for adjustment of the Exercise Price) shall thereafter be applicable, as nearly equivalent as may be practicable in relation to any share of stock, securities or assets thereafter deliverable upon the exercise thereof. The Company shall not effect any such consolidation, merger, sale, transfer or other disposition unless prior to or simultaneously with the consummation thereof the successor entity (if other than the Company) resulting from such consolidation or merger, or the entity purchasing or otherwise acquiring such assets or other appropriate corporation or entity shall assume the obligation to deliver to the Holder, at the last address of the Holder appearing on the books of the Company, such shares of stock, securities or assets as, in accordance with the foregoing provisions, the Holder may be entitled to purchase, and the other obligations under this Warrant. The provisions of this Section 6 shall similarly apply to successive reorganizations, reclassifications, consolidations, mergers, sales, transfers or other dispositions, each of which transactions shall also constitute a Fundamental Transaction.

 

7. NO SHAREHOLDER RIGHTS. Other than as provided in Section 3.2 or otherwise herein, this Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a shareholder of the Company.

 

8. TRANSFER OF WARRANT. Subject to applicable laws and the restriction on transfer set forth in the Subscription Agreement, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant and the form of assignment attached hereto to any transferee designated by Holder. The transferee shall sign an investment letter in form and substance reasonably satisfactory to the Company and its counsel. Any purported transfer of all or any portion of this Warrant in violation of the provisions of this Warrant shall be null and void.

 

9. LOST, STOLEN, MUTILATED OR DESTROYED WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.

 

10. NOTICES, ETC. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed facsimile to the facsimile number specified in writing by the recipient if sent during normal business hours of the recipient on a Trading Day, if not, then on the next Trading Day, (c) the next Trading Day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at 3180 Porter Drive, Palo Alto, CA 94304 (Att: General Counsel) and to Holder at the applicable address set forth on the applicable signature page to the Subscription Agreement or at such other address as the Company or Holder may designate by ten (10) days advance written notice to the other parties hereto.

 

4


11. ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.

 

12. GOVERNING LAW. This Warrant and all rights, obligations and liabilities hereunder shall be governed by, and construed in accordance with, the internal laws of the State of New York, without giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction.

 

13. AMENDMENT OR WAIVER. Any term of this Warrant may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) with the written consent of the Company and the holders of Company Warrants representing at least two-thirds of the number of Ordinary Shares then subject to outstanding Company Warrants. Notwithstanding the foregoing, (a) this Warrant may be amended and the observance of any term hereunder may be waived without the written consent of the Holder only in a manner which applies to all Company Warrants in the same fashion and (b) the number of Exercise Shares subject to this Warrant and the Exercise Price of this Warrant may not be amended, and the right to exercise this Warrant may not be waived, without the written consent of the Holder. The Company shall give prompt written notice to the Holder of any amendment hereof or waiver hereunder that was effected without the Holder’s written consent. No waivers of any term, condition or provision of this Warrant, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

5


IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly

authorized officer as of January 18, 2012.

 

    JAZZ PHARMACEUTICALS PLC
    By:            
        Name:  
        Title:  
      3180 Porter Drive
      Palo Alto, CA 943

 


NOTICE OF EXERCISE

 

TO:     JAZZ PHARMACEUTICALS PLC

[_]       The undersigned hereby elects to purchase [           ] Ordinary Shares of $.0001 each (the “Ordinary Shares”), of JAZZ PHARMACEUTICALS PLC (the “Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

  (1) Please issue the certificate for Ordinary Shares in the name of:

 

 

 

Print or type name

 

 

Social Security or other Identifying Number

 

 

Street Address

 

 

City State Zip Code

 

  (2) If such number of shares shall not be all the shares purchasable upon the exercise of the Warrants evidenced by this Warrant, a new warrant certificate for the balance of such Warrants remaining unexercised shall be registered in the name of and delivered to:

 

Please insert social security or other identifying number:  

   
 
(Please print name and address)

Dated:

(Date)

 

  
(Signature)
  
(Print Name)

 

2


ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:

  
(Please Print)

Address:

  
(Please Print)

Dated:     ,20[_]

Holder’s Signature:                                             

Holder’s Address:                                               

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.